KCB-328: A novel class III antiarrhythmic agent with little reverse frequency dependence in isolated guinea pig myocardium

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 4, 1998, Pages 609-617

  Lee, Kiho ^a   Lee, Ju Yeong ^a   Kim, Hak Yeop ^a   Kwon, Lae Sung ^a   Shin, Hong Sup ^a   Tanabe, Shigeru ^b   Kozono, Toshiro ^b   Park, Sung Dae ^a   Chung, You Sup ^a  

^a C and C Research Laboratories   (South Korea)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Action potential duration; Class III antiarrhythmic; Effective refractory period; KCB 328; Papillary muscle; Reverse frequency dependence

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; N [3 AMINO 4 [2 [N (3,4 DIMETHOXYPHENETHYL) N METHYLAMINO]ETHOXY]PHENYL]METHANESULFONAMIDE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; GUINEA PIG; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART PAPILLARY MUSCLE; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; REFRACTORY PERIOD;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIAC PACING, ARTIFICIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEART; MALE; MYOCARDIAL CONTRACTION; NEUROMUSCULAR DEPOLARIZING AGENTS; PAPILLARY MUSCLES; PHENETHYLAMINES; POTASSIUM CHANNEL BLOCKERS; SULFONAMIDES;

EID: 0345451162     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199804000-00021     Document Type: Article

References (41)

1. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action: effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474. Br J Pharmacol 1970;39:675-87.
2. The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
3. The CAST II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
4. Singh BN. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J 1993;14(suppl H):14-23.
5. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survival (BASIS). J Am Coll Cardiol 1990;16:1711-8.
6. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: CAMIAT pilot study. Circulation 1991;84:550-7.
7. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
8. Nademanee K, Feld G, Hendrickson J, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effect of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72: 555-64.
9. Mason JW for ESVEM investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
10. Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol 1994;9:12-22.
11. Colatsky TJ, Argentieri TM. Potassium channel blockers as antiarrhythmic drugs. Drug Dev Res 1994;33:235-49.
12. Baskin EP, Serik CM, Wallace AA, et al. Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol 1991;18:406-14.
13. K blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990;16:401-10.
14. Suzuki R, Kodama I, Iwata H, Kamiya K, Toyama J. Frequency-dependent effects of a new class-III antiarrhythmic agent, sematilide, on the action potential duration of rabbit ventricular muscles. Environ Med 1994;38:57-60.
15. Sawanobori T, Adaniya H, Namiki T, Hiraoka M. Rate-dependent effects of sematilide on action potential duration in isolated guinea pig ventricular myocytes J Pharmacol Exp Ther 1994;271:302-10.
16. Ishii M, Kamiya J, Hashimoto K. Cellular electrophysiological effects of MS-551, a new class III antiarrhythmic agent. Drug Dev Res 1995;35:61-8.
17. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-71.
18. Courtney KR. Interval-dependent effects of small antiarrhythmic drugs on excitability of guinea-pig myocardium. J Mol Cell Cardiol 1980;12:1273-86.
19. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse-use dependence. Circulation 1990;81:686-90.
20. Kim DI, Kim HY, Park SD, et al. Novel (3,4-dimethoxy)arylethylamine derivatives: a class III antiarrhythmic agent with little frequency-dependence. Abstracts XIVth International Symposium on Medicinal Chemistry, 1996:7.07.
21. Xue Y, Alita J, Hashimoto K, Tanabe S, Kim HY Effects of a new class III antiarrhythmic drug, KCB328 on canine arrhythmia models. Jpn J Pharmacol 1996;71(suppl I):138.
22. Lee JY, Lee K, Shin HS, Kim HY, Tanabe S. Frequency-dependent effects of KCB-328, a novel class III antiarrhythmic agent in isolated guinea pig ventricular muscle. FASEB J 1996;10:A32.
23. Lee K, Kwon LS, Kim HY, Tanabe S. Electrophysiological effects of KCB-328, a novel class III antiarrhythmic agent in vitro. FASEB J 1996;10:A32.
24. Molyvdas PA, Sperelakis N. Comparison of the effects of several calcium antagonistic drugs (slow-channel blockers) on the electrical and mechanical activities of guinea pig papillary muscle. J Cardiovasc Pharmacol 1983;5:162-9.
25. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibres. J Pharmacol Exp Ther 1985;232:817-25.
26. Colatsky TJ. Potassium channel blockers: synthetic agents and their antiarrhythmic potential. In: Weston AH, Hamilton TC, eds. Potassium channel modulators. Oxford: Blackwell Scientific Publications, 1992:304-40.
27. Kr blockers dofetilide, D-sotalol, E-4031, and MK-499. J Cardiovasc Pharmacol 1994;24:199-208.
28. Motomura S, Higashiyama A. Less reverse frequency dependent effects of KCB-328 on atrioventricular nodal refractoriness in the in situ dog hearts. Jpn J Pharmacol 1996;71(suppl I):229.
29. Weiss J, Shine KI. Extracellular potassium accumulation during myocardial ischaemia: implications for arrhythmogenesis. J Mol Cell Cardiol 1981;13:699-704.
30. Faber TS, Zehender M, Just H. Drug-induced torsade de pointes: incidence, management and prevention. Drug Safety 1994;11:463-76.
31. Hondeghem LM. Ideal antiarrhythmic agent: chemical defibrillators. J Cardiovasc Electrophysiol 1991;2:S169-77.
32. Anderson KP, Walker R, Dustman T, et al. Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation 1989;79:948-58.
33. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-71.
34. Sosunov EA, Anyukhovsky EP, Rosen MR. Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. J Pharmacol Exp Ther 1996;278:906-12.
35. Vrobel TR, Miller PE, Mostow ND, Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 1989;31:393-426.
36. Bril A, Dusseau C, Forest M, Cheval B, Faivre J. Comparative effects of BRL-32872 and azimilide on action potential duration in guinea-pig isolated papillary muscle. FASEB J 1996;10:A65.
37. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
38. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Circulation 1993;72:75-83.
39. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262:809-17.
40. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-68.
41. Hondeghem LM. Development of class III antiarrhythmic agents J Cardiovasc Pharmacol 1992;20(suppl 2):S17-22.